SCM
KPTI icon

Soleus Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Soleus Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Hold
440,000
– – 0.1% 75
2025
Q4 		$3.24M Buy
+440,000
New +$2.69M 0.12% 75

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Soleus Capital Management's KPTI Position: Q1 2026 in Review

Soleus Capital Management held its Karyopharm Therapeutics (KPTI) position steady in Q1 2026 at 440,000 shares worth $2.45M. The position accounts for 0.1% of the portfolio, ranked #75.

Soleus Capital Management first reported a position in KPTI in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.24M in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Soleus Capital Management held 440,000 shares of Karyopharm Therapeutics worth $2.45M as of Q1 2026.
  • Soleus Capital Management left its Karyopharm Therapeutics share count unchanged in Q1 2026.
  • Karyopharm Therapeutics made up 0.1% of Soleus Capital Management's portfolio in Q1 2026, its #75 holding.
  • Soleus Capital Management first reported a position in Karyopharm Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Soleus Capital Management's Karyopharm Therapeutics position peaked at $3.24M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.